Bränström R, et al. - In this first total population study of transgender individuals with a gender incongruence diagnosis, researchers examined the prevalence of mood and anxiety disorder health care visits and antidepressant and anxiolytic prescriptions in 2015 as a function of gender incongruence diagnosis and gender-affirming hormone and surgical treatment. For this study, they employed the Swedish Total Population Register (N = 9,747,324) and linked it to the National Patient Register and the Prescribed Drug Register. Compared with the general population, individuals with a gender incongruence diagnosis were identified to be about six times as likely to have had a mood and anxiety disorder health care visit, more than three times as likely to have got prescriptions for antidepressants and anxiolytics, and more than six times as likely to have been hospitalized after a suicide attempt. The likelihood of undergoing mental health treatment was not identified to be significantly correlated with years since initiating hormone treatment. However, there was an association of increased time since last gender-affirming surgery with decreased mental health treatment. This supports the decision to provide gender-affirming surgeries to transgender individuals who seek them.